Short term benefits to blocking a major player in the body’s immune response – (02-11-02)

Repeated infliximab, a chimeric anti-TNF alpha, in spondyloarthropathy

While there are definite short term benefits to blocking a major player in the body’s immune response, I am very concerned with the long term dangers. With this therapy, we are blocking the cytokine that maintains vigilance against cancer cells and invaders. Of additional concern in this study is that, after each infusion, more and more patients had recurrences. In addition, anti-DNA antibodies were noted in 57% of patients. These antibodies attack our own DNA.

Ann Rheum Dis — Abstracts: Kruithof et al. 61 (3): 207

Read entire article here

For more than a decade, Dr. Bogash has stayed current with the medical literature as it relates to physiology, disease prevention and disease management. He uses his knowledge to educate patients, the community and cyberspace on the best way to avoid and / or manage chronic diseases using lifestyle and targeted supplementation.







Email: